{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_018",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:f5faad19fdf03a162b0c06231a9fdd60184d1747ff0d9e9136734a653375f72e",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:01.592572",
  "content": "## 2024-07-01 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 124\n- Active: 117\n- Screen Failures Cumulative: 31\n- Withdrawals Cumulative: 7\n\n#### By Dose Group\n- Low Dose: 29\n- Mid Dose: 31\n- High Dose: 32\n- Placebo: 32\n\n### Immunogenicity By Group\n\n#### Low Dose\n- IgG Titer (GMU) Mean: 72.1\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 17.8\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 115.7\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 164.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 118.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 30.5\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 108.4\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 29.4\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 175.5\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 259.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 192.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 44.5\n\n#### High Dose\n- IgG Titer (GMU) Mean: 149.7\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 41.4\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 240.2\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 363.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 249.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 63.8\n\n#### Placebo\n- IgG Titer (GMU) Mean: 10.4\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 4.1\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 21.8\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 39.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 18.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 1.2\n\n### Injection Site Reactions\n- Pain Percentage: 35.6\n- Erythema Percentage: 23.4\n- Swelling Percentage: 11.5\n- Induration Percentage: 7.7\n- Mean Pain Duration (hours): 17.2\n\n### Systemic Reactogenicity\n- Fever Percentage: 16.1\n- Fatigue Percentage: 28.4\n- Myalgia Percentage: 20.3\n- Headache Percentage: 25.5\n- Chills Percentage: 5.7\n\n### Safety Labs\n\n#### WBC\n- Mean (K): 8.7\n- SD: 2.0\n\n#### Lymphocyte Percentage\n- Mean: 33.9\n- SD: 6.1\n\n#### Neutrophil Percentage\n- Mean: 55.2\n- SD: 8.3\n\n#### Platelets\n- Mean (K): 226\n- SD: 39\n\n#### CRP\n- Mean (mg/L): 2.3\n- SD: 0.6\n\n#### Hemoglobin\n- Mean (g/dL): 13.8\n- SD: 1.3\n\n### Adverse Events\n- AE ID: VI-AE-1847, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-1879, Description: fatigue, Grade: 2, Relatedness: related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1884, Description: chills, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- DSMB safety review teleconference completed\n- Serum sample aliquoting completed for 18 subjects\n\n### Notes\n- Week 18: Immunogenicity assessments on schedule. 124 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 18,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}